

Ref: FOIA Reference 2024/25-523

Royal Stoke University Hospital
Data, Security and Protection
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 2nd December 2024

Email foi@uhm.nhs.uk

Dear Sir/ Madam

I am writing to acknowledge receipt of your email dated 5th November 2024 requesting information under the Freedom of Information Act (2000) Multiple Myeloma

Q1 I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

A1 218

Q2 Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
- Bortezomib, thalidomide and dexamethasone [VTD]
- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
- Selinexor, Bortezomib [Velcade] and dexamethasone
- Carfilzomib [Kyprolis] and dexamethasone
- Bortezomib [Velcade] monotherapy or with dexamethasone
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
- Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
- Belantamab Mafodotin [Blenrep]
- Idecabtagene vicleucel [Abecma]
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
- Elranatamab
- Daratumumab [Darzalex] monotherapy

- **Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)**
- **Lenalidomide [Revlimid] and dexamethasone**
- **Lenalidomide [Revlimid] monotherapy**
- **Pomalidomide [Imnovid] and dexamethasone**
- **Selinexor and dexamethasone**
- **Talquetamab**
- **Teclistamab [Tecvayli]**
- **Any other systemic anti-cancer therapy**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

• Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)	5
• Bortezomib, thalidomide and dexamethasone [VTD]	0
• Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	26
• Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)	17
• Selinexor, Bortezomib [Velcade] and dexamethasone	0
• Carfilzomib [Kyprolis] and dexamethasone	0
• Bortezomib [Velcade] monotherapy or with dexamethasone	0
• Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	36
• Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone	5
• Belantamab Mafodotin [Blenrep]	6
• Idecabtagene vicleuceel [Abecma]	0
• Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)	9
• Elranatamab	<5
• Daratumumab [Darzalex] monotherapy	0
• Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)	23
• Lenalidomide [Revlimid] and	49

dexamethasone	
• Lenalidomide [Revlmid] monotherapy	31
• Pomalidomide [Imnovid] and dexamethasone	6
• Selinexor and dexamethasone	0
• Talquetamab	0
• Teclistamab [Tecvayli]	0
• Any other systemic anti-cancer therapy	21

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



University Hospitals
of North Midlands
NHS Trust

L Carlisle

Leah Carlisle

Head of Data, Security & Protection and Health Records
Data Protection Officer

